Focus: Fresenius Kabi is a Germany-based specialty pharma company focused on infusion therapy and injectable medicines across oncology, infectious diseases, immunology, nephrology, and neurology. With 5,000+ employees, it operates as a mid-cap global player in critical care and specialty pharmaceuticals.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Hot — 894 jobs added in 30d
Net +833 (894 new, 61 removed). Aggressive expansion phase.
Fresenius Kabi offers operational and manufacturing stability but carries significant single-product revenue risk and limited near-term pipeline upside; best suited for manufacturing, supply-chain, or commercial professionals seeking non-R&D growth roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (72% of portfolio); peak-stage orphan/specialty product with 9+ years of exclusivity remaining.
Help build intelligence for Fresenius Kabi
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fresenius Kabi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest franchise; peak-stage specialty immunology product with 15+ years of market protection.
Generic aromatase inhibitor in mature/post-LOE phase; declining revenue as competition intensifies.
Small-revenue generic hormone; minimal strategic importance in current portfolio.
Post-LOE antibiotic facing generic/biosimilar competition; niche market share.
Novel formulation NSAID with declining sales; LOE approaching signals imminent generic pressure.
Specialty antifungal at peak; 6+ years of exclusivity in critical-care niche.
Auto-injector franchise; recent news (Feb 2026) highlights U.S. production expansion as shortage-prone category.
Biologic hormone therapy; LOE approaching but niche market with limited competitive threat.
Small companion/alternative to VELPHORO; faces patent cliff in 2030; $388K at-risk revenue.
195 discontinued, 211 duplicate formulations not shown
+3 more products with revenue data
Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More - Yahoo Finance
Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More Yahoo Finance
Fresenius Challenges Patents To Launch IBD Drug Biosimilar - Law360
Fresenius Challenges Patents To Launch IBD Drug Biosimilar Law360
Arunesh Verma - Crain's Chicago Business
Arunesh Verma Crain's Chicago Business
Fresenius Kabi lines up full U.S. production of shortage-prone epinephrine - Crain's Chicago Business
Fresenius Kabi lines up full U.S. production of shortage-prone epinephrine Crain's Chicago Business
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Drug shortage exposure (Carboplatin, Ketorolac, Propranolol unavailable) indicates manufacturing/supply-chain challenges; recent news (Feb 2026) highlights AUVI-Q production expansion as mitigation, but systemic constraint remains.
Recent peer-reviewed publications with author affiliations at this company
Engineering a bifunctional cellobiose 2-epimerase into an isomerase capable of selective lactulose production.
Erratum to "Engineering a bifunctional cellobiose 2-epimerase into an isomerase capable of selective lactulose production" [Bioresour. Technol. 447 (2026) 134241].
+169 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo